In Depth 8 Apr 2024
A wave of biotech layoffs: will the trend continue throughout 2024?
Thousands of jobs have been at risk over the past year due to mass layoffs by biotech companies across the globe.
In Depth
- Latest Posts
In Depth 4 Apr 2024
Seven diseases CRISPR technology could cure
Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool.
In Depth 3 Apr 2024
Hepatitis B: are we edging closer to a cure?
Find out whether we are closing in on a cure for hepatitis B – a virus affecting the liver that can cause acute and chronic disease.
In Depth 27 Mar 2024
Are new treatments for multiple sclerosis on the horizon?
As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise.
In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
In Depth 21 Mar 2024
Biotech in France: What’s holding back progress and how to move forward?
Explore the latest insights from France Biotech’s ‘Panorama France HealthTech’ report, uncovering key insights of the French biotech sector.
ADVERTISEMENT
ADVERTISEMENT
In Depth 20 Mar 2024
Are molecular glues the key to undruggable targets?
As more biopharmas get sticky with molecular glue developers and venture capital interest grows, here is a review of the field.
In Depth 18 Mar 2024
Will the US biotech funding surge trigger a renaissance in the global biotech industry?
After a couple of challenging years in biotech investment, the US leads the march for recovery. Delve into the specifics driving this uptick.
In Depth 14 Mar 2024
Rett syndrome: advances in gene therapy brings hope
Explore the latest advancements in treating Rett syndrome, a rare genetic disorder, including groundbreaking gene therapies and drug trials.
In Depth 13 Mar 2024
From LSD to healing minds: Where are we standing in psychedelic drug development?
Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field.
In Depth 11 Mar 2024
Biotech bankruptcies: what to expect in 2024 following a record year?
2023 broke the record for the highest number of biotech bankruptcies in a decade. Can biotechs mitigate the risk in 2024?
In Depth 7 Mar 2024
Can AbbVie’s legacy live beyond its once best-selling drug Humira?
The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company.
ADVERTISEMENT
